A Randomized Cost-Minimization Trial Comparing Pemetrexed (Alimta) Versus Docetaxel (Taxotere) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study 05-06 of Groupe Francais de Pneumo-Cancerologie (GFPC).

Trial Profile

A Randomized Cost-Minimization Trial Comparing Pemetrexed (Alimta) Versus Docetaxel (Taxotere) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study 05-06 of Groupe Francais de Pneumo-Cancerologie (GFPC).

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2010

At a glance

  • Drugs Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Oct 2009 Results presented at ISPOR 2009.
    • 25 Aug 2009 Planned end date (Dec 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top